Loading...
Docoh

AMGEN (AMGN)

News

From Benzinga Pro
$100 Invested In This Stock 15 Years Ago Would Be Worth $400 Today
21 Sep 22
Earnings, News, Dividends
Amgen (NASDAQ:AMGN) has outperformed the market over the past 15 years by 3.43% on an annualized basis producing an average annual return of 9.79%. Currently, Amgen has a market capitalization of $122.73 billion.
Top US Drugmakers Exploit US Patent System To Keep Generic Competition At Bay: Report
16 Sep 22
Biotech, Large Cap, News, Health Care, Legal, General
US Department Of Health, Defense To Inject $1B To Boost Domestic Biomanufacturing
14 Sep 22
Biotech, Government, News, Health Care, Financing, General
Amgen Whale Trades Spotted
13 Sep 22
Options, Markets
A whale with a lot of money to spend has taken a noticeably bearish stance on Amgen. Looking at options history for Amgen (NASDAQ:AMGN) we detected 22 strange trades.
Biden Administration Pushes 'Cancer Moonshot' Initiative: Report
13 Sep 22
Biotech, Government, News, Health Care, Politics, General
President Joe Biden channeled John F. Kennedy on the 60th anniversary of the former President's moonshot speech, highlighting the Biden administration's efforts to "end cancer as we know it." The President underscored his goal to cut the cancer death rate in the U.S. by at least 50% over the next 25 years.
Livent, Amgen And Some Other Big Stocks Moving Lower On Monday
12 Sep 22
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
U.S. stocks traded higher, with the Dow Jones gaining more than 250 points on Monday. Here are some big stocks recording gains in today’s session.
'Data Likely Support Approval Of Amgen's KRAS-targeted Drug, But Still Come With Disappointments' -Stat News
12 Sep 22
News
https://www.statnews.com/2022/09/12/data-likely-support-approval-of-amgens-kras-targeted-drug-but-still-come-with-disappointments/
Here's Why Amgen Shares Are Diving
12 Sep 22
Short Ideas, Trading Ideas
Amgen, Inc. (NASDAQ: AMGN) shares are trading lower by 4.11% to $237.51 during Monday's pre-market session following FDA approval of Bristol Myers Squibb Co's (NYSE: BMY) plaque psoriasis drug Sotyktu, which s
Top Financial Stories Monday, September 12: Netflix Collaborates With Assassin's Creed Maker, Gun Sales Could Soon Be Tracked Via Payment Processors, Xi Jinping To Meet Vladimir Putin In First Foreign Trip And More...
12 Sep 22
Biotech, Cryptocurrency, Earnings, M&A, News, Health Care, Legal, Top Stories, Markets, Movers, Tech, Media, Trading Ideas, General
Bloomberg Tesla, Nio Supplier CATL's Chinese Rival Eyes $2B Hong Kong IPO
Amgen's Lumakras Cuts Risk Of Progression By 34% In KRAS-Mutated Lung Cancer Patients
12 Sep 22
Biotech, Large Cap, News, Health Care, Movers, Trading Ideas, General
Bristol Myers' Deucravacitinib Scores FDA Approval For Plaque Psoriasis
12 Sep 22
Biotech, Large Cap, News, Health Care, FDA, Movers, Trading Ideas, General
Amgen Says SPROUT Data Show Otezla Resulted In 'Significant Improvements' In Measures Of Moderate To Severe Plaque Psoriasis At Week 16 Compared With Placebo In Children Ages 6-17
8 Sep 22
Biotech, News, FDA, General
AMGEN ANNOUNCES POSITIVE NEW DATA AT EADV 2022 FOR OTEZLA® (APREMILAST) SPROUT Data Show Otezla Resulted in Significant Improvements in Measures of Moderate to Severe Plaque Psoriasis at Week 16 Compared With
These 3 S&P 500 Dividend Stocks Have High Compound Annual Growth Rates Through 2024
3 Sep 22
Large Cap, Long Ideas, Mid Cap, News, Guidance, Dividends, Dividends, Trading Ideas
Based on consensus estimates among surveyed analysts, FactSet has determined which stocks in the S&P 500 that have the highest expected two-year dividend compound annual growth rate.
Here's How Much You Would Have Made Owning Amgen Stock In The Last 20 Years
1 Sep 22
Earnings, News, Dividends
Amgen (NASDAQ:AMGN) has outperformed the market over the past 20 years by 1.16% on an annualized basis producing an average annual return of 8.7%. Currently, Amgen has a market capitalization of $130.65 billion.
Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know
31 Aug 22
Biotech, News, Penny Stocks, Small Cap, FDA, Top Stories, Trading Ideas, General
After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar.
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary
30 Aug 22
Biotech, Penny Stocks, Health Care, Small Cap, General
Amgen Shares Climb As Late-Stage Lung Cancer Study Meets Primary Endpoint
30 Aug 22
Biotech, Health Care, General
Amgen (NASDAQ: AMGN) has announced top-line results from the global Phase 3 CodeBreaK 200 trial evaluating once daily oral LUMAKRAS (sotorasib) in patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC).
Amgen Announces Topline Data From Lumakras Phase 3 Trial In Non-small Cell Lung Cancer Met Its Primary Endpoint
30 Aug 22
Biotech, News, FDA, General
LUMAKRAS Met Primary Endpoint of Progression-Free Survival, Demonstrating Superiority Over Standard of Care Docetaxel Chemotherapy, in KRAS G12C-Mutated Non-Small Cell Lung Cancer Detailed Data to be Presented
Amgen To Present New Clinical And Real-world Data Across Inflammation Portfolio At EADV September 7-10 2022
30 Aug 22
Large Cap, News
New Positive Data From Phase 3 SPROUT Trial, Studying Otezla (apremilast) in Children Ages 6-17 With Moderate to Severe Plaque Psoriasis Positive Results From the Phase 3 DISCREET Study, Investigating Clinical Efficacy
Amgen's Repatha Shows Long Term Lowering Of Bad Cholesterol, Tolerance
29 Aug 22
Biotech, News, Health Care, General

Press releases

From Benzinga Pro
AMGEN ANNOUNCES WEBCAST OF 2022 BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE
12 Sep 22
Press Releases
THOUSAND OAKS, Calif., Sept. 12, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Bank of America Merrill Lynch's 2022 Global Healthcare Conference at 4:55 a.m. ET on Thursday, Sept. 15, 2022. Peter H.
LUMAKRAS® (SOTORASIB) COMBINED WITH VECTIBIX® (PANITUMUMAB) SHOWS CONFIRMED 30% OBJECTIVE RESPONSE RATE IN PATIENTS WITH KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER
12 Sep 22
Press Releases
Phase 1b Results Demonstrate Encouraging Median Progression-Free Survival of 5.7 Months in Difficult-to-Treat Patient Population THOUSAND OAKS, Calif., Sept. 12, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced
LUMAKRAS®/LUMYKRAS® (SOTORASIB) DEMONSTRATES SUPERIOR PROGRESSION-FREE SURVIVAL OVER DOCETAXEL IN FIRST POSITIVE PHASE 3 TRIAL OF A KRAS G12C INHIBITOR IN NON-SMALL CELL LUNG CANCER
11 Sep 22
Press Releases
At 1-Year, Progression-Free Survival was 25% for LUMAKRAS Versus 10% for Docetaxel LUMAKRAS Met Key Secondary Endpoint of Objective Response Rate THOUSAND OAKS, Calif., Sept. 11, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN)
AMGEN ANNOUNCES WEBCAST OF 2022 MORGAN STANLEY GLOBAL HEALTHCARE CONFERENCE
8 Sep 22
Press Releases
THOUSAND OAKS, Calif., Sept. 8, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Morgan Stanley's 2022 Global Healthcare Conference at 9:10 a.m. ET on Tuesday, Sept. 13, 2022. Robert A. Bradway, chairman and
AMGEN ANNOUNCES POSITIVE NEW DATA AT EADV 2022 FOR OTEZLA® (APREMILAST)
8 Sep 22
Press Releases
SPROUT Data Show Otezla Resulted in Significant Improvements in Measures of Moderate to Severe Plaque Psoriasis at Week 16 Compared With Placebo in Children Ages 6-171 DISCREET 16-week Data Demonstrated Statistically
AMGEN TO WEBCAST INVESTOR CALL AT ESMO 2022
7 Sep 22
Press Releases
THOUSAND OAKS, Calif., Sept. 7, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the European Society for Medical Oncology Annual Congress (ESMO) at 1:30
AMGEN ANNOUNCES WEBCAST OF 2022 WELLS FARGO HEALTHCARE CONFERENCE
2 Sep 22
Press Releases
THOUSAND OAKS, Calif., Sept. 2, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Wells Fargo's 2022 Global Healthcare Conference at 9:45 a.m. ET on Thursday, September 8, 2022. David M. Reese, M.D., executive
AMGEN ANNOUNCES WEBCAST OF 2022 CITI GLOBAL HEALTHCARE CONFERENCE
2 Sep 22
Press Releases
THOUSAND OAKS, Calif., Sept. 2, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Citi's 2022 Global Healthcare Conference at 8:50 a.m. ET on Wednesday, September 7, 2022. David M. Reese, M.D., executive vice
AMGEN ANNOUNCES TOPLINE DATA FROM LUMAKRAS® (SOTORASIB) PHASE 3 TRIAL IN NON-SMALL CELL LUNG CANCER
30 Aug 22
Press Releases
LUMAKRAS Met Primary Endpoint of Progression-Free Survival, Demonstrating Superiority Over Standard of Care Docetaxel Chemotherapy, in KRAS G12C-Mutated Non-Small Cell Lung Cancer Detailed Data to be Presented at an
NEW AMGEN DATA AT ESC 2022 SHOW LONG-TERM LDL-C LOWERING WITH REPATHA® (EVOLOCUMAB) WAS WELL-TOLERATED FOR MORE THAN 8 YEARS
29 Aug 22
Press Releases
Earlier Treatment With Repatha Resulted in a Lower Incidence of Major CV Events, Including CV Death 80% of Patients Achieved Guideline Directed LDL-C Levels of <55 mg/dL at Week 12 Data Presented at ESC 2022 and
AMGEN ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY OF ABP 959, BIOSIMILAR CANDIDATE TO SOLIRIS® (ECULIZUMAB)
23 Aug 22
Press Releases
Study Evaluated the Efficacy, Safety and Immunogenicity of ABP 959 Compared to Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria THOUSAND OAKS, Calif., Aug. 23, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN)
AMGEN TO PRESENT NEW DATA AT ESC CONGRESS 2022 HIGHLIGHTING UP TO 8.5 YEARS OF REPATHA® (EVOLOCUMAB) SAFETY AND TOLERABILITY DATA IN HIGH-RISK ASCVD PATIENT POPULATIONS
22 Aug 22
Press Releases
Late-breaking Hot Line Oral Presentation on FOURIER-OLE Data Represents Longest Trials of a PCSK9i to Date New HEYMANS, HAUSER Data to be Presented THOUSAND OAKS, Calif., Aug. 22, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN)
AMGEN PRESENTS NEW TARLATAMAB CLINICAL DATA AT WCLC 2022
8 Aug 22
Press Releases
Phase 1 Tarlatamab Study Showed Encouraging Antitumor Activity With Median Duration of Response of 13 Months in Small Cell Lung Cancer No Approved Treatment Options Available to Patients in Third-line Setting THOUSAND
CHEMOCENTRYX, INC. ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of CCXI and Encourages Investors to Contact the Firm
7 Aug 22
News, Legal, Press Releases
NEW YORK, Aug. 07, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of ChemoCentryx,
AMGEN DATA AT WCLC 2022 HIGHLIGHTS POTENTIAL TO DELIVER TRANSFORMATIVE MEDICINES FOR HISTORICALLY DIFFICULT-TO-TREAT LUNG CANCERS
7 Aug 22
Press Releases
First Data From LUMAKRAS Plus Immunotherapy and LUMAKRAS Plus SHP2 Inhibitor Combinations Show Clinical Activity and Support Ongoing Investigation Updated Phase 1 Tarlatamab Data Reinforce Potential of BiTE®
SHAREHOLDER ALERT: Weiss Law Investigates ChemoCentryx, Inc
4 Aug 22
Press Releases
NEW YORK, Aug. 4, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of ChemoCentryx, Inc. ("ChemoCentryx" or the
AMGEN REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS
4 Aug 22
Earnings, Press Releases
THOUSAND OAKS, Calif., Aug. 4, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2022. Key results include: Total revenues increased 1% to $6.6 billion in comparison to
AMGEN TO ACQUIRE CHEMOCENTRYX FOR $4 BILLION IN CASH
4 Aug 22
Press Releases
Acquisition Includes TAVNEOS® (avacopan), a First-in-Class Medicine for Patients With Serious Autoimmune Disease Tavneos Adds to Amgen's Decades-Long Leadership in Inflammation and Nephrology THOUSAND OAKS,
AMGEN APPOINTS MICHAEL V. DRAKE TO BOARD OF DIRECTORS
3 Aug 22
Press Releases
THOUSAND OAKS, Calif., Aug. 3, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the appointment of Michael V. Drake, M.D., to its Board of Directors, effective immediately. Dr. Drake will also serve as a member
AMGEN ANNOUNCES 2022 THIRD QUARTER DIVIDEND
3 Aug 22
Dividends, Press Releases
THOUSAND OAKS, Calif., Aug. 3, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.94 per share dividend for the third quarter of 2022. The dividend will be paid on